New Commercial Partnership in Ukraine

Probiotix Health PLC

03 October 2024

 

3 October 2024

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

New Commercial Partnership in Ukraine

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces a commercial partnership with Ukraine based pharmaceutical distributor Deutsch-Pharm Lcc ("Deutsch-Pharm").

Deutsch-Pharm is one of the leading pharmaceutical product distributors in Ukraine, working with over 9,000 customers and partners in the country, supplying products to hospitals, pharmacies and online stores. Deutsch-Pharm works with leading players including Bufour, Ipensa, Hoffmann la Roche and Fresenius.

Deutsch-Pharm will utilise two of the Company's products initially: YouBiotix_X3 , targeting cholesterol lowering, and YourBiotix_VH, targeting general vascular health. Both products will be introduced under Deutsch-Pharm's own brand.

Ukraine has a population of 38 million people and suffers from high cardiovascular disease rates as well as an ageing population. Indeed, the World Health Organisation ("WHO") estimates that over 40% of the adult population have elevated cholesterol levels, so would benefit from preventive interventions. Until recently no natural preventative clinically documented  dietary supplements have been available to consumers in Ukraine.

The partnership with Deutsch-Pharm will see an initial focus on the Ukrainian market followed by Uzbekistan and other countries in the region. There will be a 3 to6 month product registration process with commercialisation expected during Q1 2025.

Steen Andersen, CEO of ProBiotix, commented: "We are excited for the opportunity to work with a leading company like Deutsch-Pharm to open up this region for our probiotic products based on LP_LDL ®.

"Through this significant cooperation our products will become available to Ukrainian consumers through brick and mortar pharmacies as well as online stores, providing an excellent opportunity to be positioned by a professional partner with a strong position and an in depth understating of the market dynamics in Ukraine.

"We have high aspirations for this collaboration which we are convinced will be a springboard for further successful expansion into other adjacent countries."

Pavlo Huzar, General Director of Deutsch-Pharm, added: "We are very pleased to start this partnership with ProBiotix Health. This is another important step towards the implementation of our mission to provide consumers in Ukraine and other selected countries in the region with innovative, efficacious, and economically feasible products.

We are increasingly building our own product line, so the collaboration with ProBiotix is an important development for us and we are thrilled to have the opportunity to introduce the scientifically proven products from ProBiotix Health under our own brand. We are convinced that these products will help many people in the Ukraine who are looking for a safe and effective way to solve challenges with high cholesterol levels."

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive Officer	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)		Tel: [phone]
Mark Anwyl
Walbrook PR Ltd	[e-mail]
Anna Dunphy	Mob: [phone]

 

END